We previously reported that the peptide antagonist of CXCR4, TN140, significantly reduced BM leukemic burden in PDX AML models with high CXCR4 expression but it was not active in CXCR4-low PDX models22. The gene discussed is CXCR4; the disease is acute myeloid leukemia.